BRPI0821168B8 - anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma - Google Patents

anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma

Info

Publication number
BRPI0821168B8
BRPI0821168B8 BRPI0821168A BRPI0821168A BRPI0821168B8 BR PI0821168 B8 BRPI0821168 B8 BR PI0821168B8 BR PI0821168 A BRPI0821168 A BR PI0821168A BR PI0821168 A BRPI0821168 A BR PI0821168A BR PI0821168 B8 BRPI0821168 B8 BR PI0821168B8
Authority
BR
Brazil
Prior art keywords
human
fragment
antibody
binds
cells
Prior art date
Application number
BRPI0821168A
Other languages
English (en)
Portuguese (pt)
Inventor
M Krejsa Cecile
C Yi Eugene
J Ramsdell Frederick
W Rixon Mark
R Dillon Stacey
R Jaspers Stephen
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BRPI0821168A2 publication Critical patent/BRPI0821168A2/pt
Publication of BRPI0821168B1 publication Critical patent/BRPI0821168B1/pt
Publication of BRPI0821168B8 publication Critical patent/BRPI0821168B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
BRPI0821168A 2007-12-07 2008-12-08 anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma BRPI0821168B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1232907P 2007-12-07 2007-12-07
US61/012329 2007-12-07
PCT/IB2008/005011 WO2010055366A2 (en) 2007-12-07 2008-12-08 Anti-human il-21 monoclonal antibodies

Publications (3)

Publication Number Publication Date
BRPI0821168A2 BRPI0821168A2 (pt) 2015-10-27
BRPI0821168B1 BRPI0821168B1 (pt) 2021-01-12
BRPI0821168B8 true BRPI0821168B8 (pt) 2021-05-25

Family

ID=40899470

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821168A BRPI0821168B8 (pt) 2007-12-07 2008-12-08 anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma

Country Status (18)

Country Link
US (5) US7883700B2 (enExample)
EP (3) EP2217268B1 (enExample)
JP (3) JP5745274B2 (enExample)
KR (2) KR101591316B1 (enExample)
CN (2) CN102027011B (enExample)
AU (1) AU2008364115B2 (enExample)
BR (1) BRPI0821168B8 (enExample)
CA (2) CA2910933C (enExample)
DK (1) DK2217268T3 (enExample)
ES (2) ES2584237T3 (enExample)
HU (1) HUE027828T2 (enExample)
IL (2) IL205976A (enExample)
MX (1) MX2010006181A (enExample)
PL (1) PL2217268T3 (enExample)
PT (1) PT2217268T (enExample)
RU (1) RU2504552C2 (enExample)
WO (1) WO2010055366A2 (enExample)
ZA (1) ZA201004046B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
EP2217268B1 (en) 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
US20130224109A1 (en) * 2010-07-20 2013-08-29 Beth Israel Deaconess Medical Center, Inc. Compositions and methods featuring il-6 and il-21 antagonists
US20130323259A1 (en) * 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
WO2012164021A1 (en) 2011-05-31 2012-12-06 Novo Nordisk A/S Il-21 epitope and il-21 ligands
EP2768859B1 (en) * 2011-10-19 2018-02-21 MorphoSys AG Antagonists of il17c for the treatment of inflammatory disorders
EP2746293A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of cardiovascular diseases
US20140178395A1 (en) * 2012-12-21 2014-06-26 Novo Nordisk A/S Treatment of nephropathy
WO2014205501A1 (en) * 2013-06-27 2014-12-31 Monash University Il-21 binding proteins and uses thereof
CN103487572B (zh) * 2013-10-08 2017-03-29 北京大学人民医院 滤泡辅助性T淋巴细胞(Tfh)在自身免疫性疾病病情预警中的应用
CN104721820A (zh) * 2013-12-24 2015-06-24 信达生物制药(苏州)有限公司 双特异性单克隆抗体在治疗葡萄膜炎中的用途
WO2015132241A1 (en) * 2014-03-03 2015-09-11 Novo Nordisk A/S Treatment of inflammatory diseases
AR099625A1 (es) 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
PT3139948T (pt) * 2014-05-07 2020-05-22 Novo Nordisk As Tratamento de diabetes usando glp-1 e anti-il-21
JP6672175B2 (ja) * 2014-05-07 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
CN107249633A (zh) * 2014-12-19 2017-10-13 迈博太科公司 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法
EP3233120A4 (en) 2014-12-19 2018-05-30 Monash University Il-21 antibodies
CA3018792C (en) 2016-03-31 2023-03-28 Eli Lilly And Company Il-21 antibodies and uses thereof
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
JP6952295B2 (ja) * 2016-09-09 2021-10-20 国立大学法人金沢大学 ヒト抗ｈｌａモノクローナル抗体の作製方法
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
KR20230038496A (ko) * 2020-07-13 2023-03-20 트랜스진 면역 억제의 치료
CN118370816A (zh) * 2024-03-22 2024-07-23 中日友好医院(中日友好临床医学研究所) Il-2/抗il-2抗体免疫复合物的应用
WO2025257327A1 (en) 2024-06-13 2025-12-18 Almirall, S.A. Therapeutic approaches for the management of hidradenitis suppurativa

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
UA84387C2 (ru) 1999-03-09 2008-10-27 Займодженетикс, Инк. Человеческий цитокин как лиганд зальфа рецептора и его применение
ES2279809T3 (es) 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
ES2286128T3 (es) 2000-06-30 2007-12-01 Zymogenetics, Inc. Proteina zcyto21 tipo interferon.
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
EP2130919A1 (en) * 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
US20040028665A1 (en) * 2002-01-08 2004-02-12 Garner Bryan E. Compositions and methods for inhibiting pathogenic growth
AU2003230834A1 (en) 2002-04-09 2003-10-27 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
KR20050065587A (ko) 2002-10-08 2005-06-29 이뮤노메딕스, 인코오포레이티드 항체 치료법
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
MXPA05006117A (es) 2002-12-13 2005-09-30 Zymogenetics Inc Produccion de il-21 en hospederos procarioticos.
AU2003294930B2 (en) 2002-12-23 2008-12-04 Innate Pharma Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
RU2005132458A (ru) * 2003-03-21 2006-03-20 Уайт (Us) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
EP1680138B1 (en) 2003-10-17 2013-07-17 Novo Nordisk A/S Combination therapy
JP4471721B2 (ja) 2004-04-20 2010-06-02 独立行政法人産業技術総合研究所 抗インターロイキン２１受容体（ｉｌ−２１ｒ）抗体および本抗体を産生するハイブリドーマ
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
MX2007001509A (es) 2004-08-05 2007-03-27 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina 21.
KR100654124B1 (ko) 2004-11-18 2006-12-08 주식회사 하이닉스반도체 벙커 디펙트를 억제할 수 있는 반도체 소자 제조 방법
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
WO2006105538A2 (en) * 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
DK200501310A (da) * 2005-09-21 2005-10-01 Novo Nordisk As The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
EP1960433A2 (en) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Il-21 receptor antagonists
EP2217268B1 (en) 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies

Also Published As

Publication number Publication date
WO2010055366A3 (en) 2010-10-21
AU2008364115B2 (en) 2013-11-21
CN103772502A (zh) 2014-05-07
KR101615215B1 (ko) 2016-04-25
JP2014129387A (ja) 2014-07-10
US20120225065A1 (en) 2012-09-06
US8241629B2 (en) 2012-08-14
EP2426146B1 (en) 2016-02-17
HUE027828T2 (en) 2016-11-28
PL2217268T3 (pl) 2016-12-30
IL239947A (en) 2016-03-31
CN102027011B (zh) 2014-09-03
CA2910933A1 (en) 2010-05-20
ES2584237T3 (es) 2016-09-26
US8226948B1 (en) 2012-07-24
IL205976A0 (en) 2010-11-30
ZA201004046B (en) 2011-04-28
WO2010055366A4 (en) 2012-08-16
IL239947A0 (en) 2015-08-31
JP2016033150A (ja) 2016-03-10
CN102027011A (zh) 2011-04-20
DK2217268T3 (en) 2016-08-15
US20120177655A1 (en) 2012-07-12
JP5745274B2 (ja) 2015-07-08
US8124089B2 (en) 2012-02-28
US20090191214A1 (en) 2009-07-30
EP2217268A2 (en) 2010-08-18
JP6027668B2 (ja) 2016-11-16
EP2426146A2 (en) 2012-03-07
KR101591316B1 (ko) 2016-02-05
JP2011506422A (ja) 2011-03-03
US20110130548A1 (en) 2011-06-02
RU2504552C2 (ru) 2014-01-20
EP2426146A3 (en) 2012-05-30
KR20160022386A (ko) 2016-02-29
CA2910933C (en) 2017-04-11
US20100041873A1 (en) 2010-02-18
IL205976A (en) 2015-08-31
MX2010006181A (es) 2010-07-01
US8361470B2 (en) 2013-01-29
ES2572231T3 (es) 2016-05-30
WO2010055366A2 (en) 2010-05-20
US7883700B2 (en) 2011-02-08
JP5848384B2 (ja) 2016-01-27
CA2707026C (en) 2017-04-11
CA2707026A1 (en) 2010-05-20
AU2008364115A1 (en) 2010-05-20
PT2217268T (pt) 2016-07-28
EP2217268B1 (en) 2016-05-04
BRPI0821168B1 (pt) 2021-01-12
RU2010123049A (ru) 2012-01-20
CN103772502B (zh) 2017-03-29
KR20100097724A (ko) 2010-09-03
BRPI0821168A2 (pt) 2015-10-27
EP3103813A1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
MX2010006181A (es) Anticuerpos monoclonales il-21 anti-humanos.
JP7257971B6 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
ES2494190T3 (es) Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
RU2012129735A (ru) Антитела к her3 и их применения
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
MA32725B1 (fr) Anticorps contre l'il 17 humaine et utilisations associees
PE20211293A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
AR067199A1 (es) Proteinas de union a antigenos que se unen a par-2
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
PE20190976A1 (es) Anticuerpos de union a cd3
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
HRP20201191T1 (hr) Mutirani multispecifični fab fragmenti antitijela
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
CY1115906T1 (el) Ανθρωποποιημενα αντισωματα κατα του βητα αμυλοειδους
CY1115456T1 (el) Μεθοδος χορηγησης αντισωματων αντι-ιl-5
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
AR058955A1 (es) Inmunglobulinas que se unen a interleuquina 13
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
PE20081625A1 (es) Proteinas de union al antigeno del receptor a de la il-17
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.1 NA RPI NO 2589 DE 18/08/2020 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF